Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

291
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
291
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

236
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
236
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

243
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
243
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

274
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
274
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same author

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.

Vaccine·2026
Same author

Towards elimination of viral hepatitis in the Czech Republic, Hungary, Poland and Slovakia: insights from the Viral Hepatitis Prevention Board (VHPB).

Clinical and experimental hepatology·2026
Same author

<i>Plasmodium falciparum</i> Malaria and Arbovirus Co-Exposure in the Boende Health Zone, Northwestern Democratic Republic of the Congo.

Tropical medicine and infectious disease·2026
Same author

Prevalence of hepatitis B surface antibodies and hepatitis B exposure in Belgium: results from a nationwide population-based serosurvey.

BMC infectious diseases·2026
Same author

Commentary: 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea.

Frontiers in public health·2026

Related Experiment Video

Updated: Jan 31, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Hepatitis B and the need for a booster dose.

Elke Leuridan1, Pierre Van Damme

  • 1Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Edegem, Belgium. elke.leuridan@ua.ac.be

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 10, 2011
PubMed
Summary

Hepatitis B virus (HBV) vaccination provides long-term protection in most individuals, even as antibody levels decline. Boosters are generally unnecessary for immunocompetent persons but recommended for immunocompromised patients based on monitoring.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

30.4K

Related Experiment Videos

Last Updated: Jan 31, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

30.4K

Area of Science:

  • Immunology
  • Virology
  • Public Health

Background:

  • Hepatitis B virus (HBV) vaccination is a cornerstone of infectious disease prevention.
  • Decades of widespread vaccination necessitate evaluating long-term immunity and the need for booster doses.

Purpose of the Study:

  • To assess the necessity of booster doses for hepatitis B virus (HBV) vaccination.
  • To evaluate the durability of long-term protection conferred by the primary HBV immunization course.

Main Methods:

  • Assessing anamnestic responses to booster doses.
  • Monitoring HBV infection rates in vaccinated cohorts.
  • Evaluating in vitro B and T cell activity.
  • Conducting seroepidemiological studies to track antibody levels and immunity over time.

Main Results:

  • Long-term protection persists despite declining anti-hepatitis B surface antibody titers.
  • Studies up to 20 years post-immunization show sustained protection in immunocompetent individuals.
  • The precise mechanisms underlying this durable immunity require further elucidation.

Conclusions:

  • Booster doses are not required for immunocompetent individuals who completed the primary HBV vaccination series.
  • Immunocompromised patients may benefit from booster doses, guided by serological monitoring.
  • Continued research into the immunological memory of HBV vaccination is warranted.